Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intas Pharma

- PMLiVE

Teva circling as Perrigo rejects second Mylan offer

Claims latest offer is lower than a recent informal bid

- PMLiVE

Teva offers $40bn for Mylan as Perrigo backs away

Generic drug industry could be shaken up if deals go through

Teva Pharma logo

Teva slapped with $512m fine on pay-for-delay deal

Israeli firm pays out to settle claims it hindered use of generic Provigil

Daiichi Sankyo logo

Daiichi Sankyo offloads stake in India’s Sun Pharma

Japanese firm wants to shed its share of the generic Indian drugmaker

- PMLiVE

Rise of generics will curb France’s pharma growth

Generics are set to take a serious bite out of the market as a cash-strapped government pushes for cost controls

- PMLiVE

First generic version of Teva’s Copaxone cleared by FDA

Will be marketed as Glatopa by Momenta and Novartis’ Sandoz subsidiary

- PMLiVE

Gilead under fire for Sovaldi anti-diversion policy

Accused as generic versions of the drug start to reach the market

Teva Pharma logo

Teva starts M&A push with $3.5bn Auspex buy

Aims to diversify business away from dependency on Copaxone

UK Life Sciences Strategy - one year on

AstraZeneca joins Genomics England consortium

Combines with other pharma firms such as Illumina to utilise genetic data to create new medicines

Teva appoints Timothy Wright as business development head

The former Covidien Pharma president mostrecently led a US cancer centre

Actavis makes two additions to board of directors

Michael R Gallagher and Peter J McDonnell join

- PMLiVE

Actavis completes $70.5bn Allergan acquisition

Finalisation comes after bidding war with deal-hungry Valeant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links